Evolution of the mCRPC treatment landscape


A new article by Jeffress in the cancer business publication OBR Green discusses the changing patterns of use of  the various approved drugs in the treatment of metastatic, castration-resistant prostate cancer (mCRPC).

The decline in the use of docetaxel as compared to the rise in the uses of other agents over the past 4 years is striking. Obviously, however, this article was written before the approval of enzalutamide (Xtandi) in the treatment of chemotherapy-naïve mCRPC and before the recent manufacturing problem encountered in relation to supply of radium-223 (Xofigo).

The article also draws attention to the projected announcement of results from Phase III trials of tasquinimod in asymptomatic or minimally symptomatic mCRPC in 2014; of cabazitaxel (Jevtana) in chemotherapy-naïve mCRPC in early 2015; and of ipilimumab (Yervoy) in chemotherapy-naïve mCRPC in 2015. And then there are also the ongoing trials of such agents as PROSTVAC and ARN-509 still to come as well.

One Response

  1. Very interesting for me to see the changing landscape of mCRPC expressed from a business perspective. Thank you for posting this article.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: